

SeaSpine Holdings Corp
 Form 4
 July 06, 2015

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Integra LifeSciences Corp

2. Issuer Name and Ticker or Trading Symbol
 SeaSpine Holdings Corp [SPNE]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
 311 ENTERPRISE DRIVE
 (Street)

3. Date of Earliest Transaction
 (Month/Day/Year)
 07/01/2015

___ Director ___X___ 10% Owner
 ___ Officer (give title below) ___ Other (specify below)

PLAINSBORO, NJ 08536

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 ___ Form filed by One Reporting Person
 ___X___ Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2015		J ⁽¹⁾		10,955,413 ⁽²⁾	D	\$ 0 0
						I	See footnote ⁽³⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: SeaSpine Holdings Corp - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Following Reporting Transaction (Instr. 6)
--	--	--------------------------------------	--	--------------------------------	---	--	---	--	---

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Integra LifeSciences Corp 311 ENTERPRISE DRIVE PLAINSBORO, NJ 08536		X		
INTEGRA LIFESCIENCES HOLDINGS CORP 311 ENTERPRISE DRIVE PLAINSBORO, NJ 08536		X		

Signatures

Integra Lifesciences Corporation By: Integra Lifesciences Holdings Corporation By: /s/ Richard D. Gorelick, Corporate Vice President, General Counsel, Administration and Secretary 07/06/2015

__Signature of Reporting Person Date

Integra Lifesciences Holdings Corporation By: /s/ Richard D. Gorelick, Corporate Vice President, General Counsel, Administration and Secretary 07/06/2015

__Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Integra Lifesciences Holding Corporation distributed the shares to its shareholders on a pro rata basis in connection with the separation of the Issuer from Integra Lifesciences Holdings Corporation on July 1, 2015 (the "Separation").
- (2) On June 30, 2015, the common stock of the Issuer split 109,554.13-for-1, resulting in the reporting persons' ownership of a total of 10,955,413 shares of common stock.
- (3) Prior to the Separation, SeaSpine Holdings Corporation was a wholly-owned subsidiary of Integra Lifesciences Corporation, which is a wholly-owned subsidiary of Integra Lifesciences Holdings Corporation.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.